Last update 23 Jan 2025

Anmai Biotechnology (Suzhou) Co., Ltd.

Private Company|
2018|
Jiangsu Sheng, China

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Digestive System Disorders
Bispecific antibody
Bispecific T-cell Engager (BiTE)

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Endocrinology and Metabolic Disease3
Hemic and Lymphatic Diseases1
Infectious Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Bispecific antibody3
Bispecific T-cell Engager (BiTE)1
Top 5 TargetCount
OX40 x PDL11
LAG3 x PD-11
CD3 x ROR11
EGFR x c-Met1

Related

4
Drugs associated with Anmai Biotechnology (Suzhou) Co., Ltd.
Bafisontamab
Target
EGFR x c-Met
Mechanism
EGFR antagonists [+1]
Active Org.
EpimAb Biotherapeutics, Inc.EpimAb Biotherapeutics, Inc. [+1]
Originator Org.
EpimAb Biotherapeutics, Inc.EpimAb Biotherapeutics, Inc.
Active Indication
Non-Small Cell Lung Cancer [+9]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Fanastomig
Target
LAG3 x PD-1
Mechanism
LAG3 inhibitors [+1]
Active Org.
Anmai Biotechnology (Suzhou) Co., Ltd.
Originator Org.
EpimAb Biotherapeutics, Inc.EpimAb Biotherapeutics, Inc.
Active Indication
Solid tumor
Inactive Indication
Advanced Malignant Solid Neoplasm
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
EMB-09
Target
OX40 x PDL1
Mechanism
OX40 inhibitors [+1]
Active Org.
EpimAb Biotherapeutics, Inc.EpimAb Biotherapeutics, Inc. [+1]
Originator Org.
EpimAb Biotherapeutics, Inc.EpimAb Biotherapeutics, Inc.
Active Indication
Advanced Malignant Solid Neoplasm [+15]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Anmai Biotechnology (Suzhou) Co., Ltd.
CTR20230350
/ RecruitingPhase 1
一项EMB-07（一种双特异性抗体抗CD3和受体酪氨酸激酶样孤儿受体1[ROR1]）在局部晚期/转移性实体瘤或复发性/难治性淋巴瘤患者中的首次人体I期开放性研究
[Translation] A first-in-human Phase I open-label study of EMB-07, a bispecific antibody against CD3 and receptor tyrosine kinase-like orphan receptor 1 [ROR1], in patients with locally advanced/metastatic solid tumors or relapsed/refractory lymphoma
NCT05607498
/ RecruitingPhase 1
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
100 Clinical Results associated with Anmai Biotechnology (Suzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Anmai Biotechnology (Suzhou) Co., Ltd.
Login to view more data
100 Deals associated with Anmai Biotechnology (Suzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Anmai Biotechnology (Suzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
2
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Fanastomig
 ( LAG3 x PD-1 )		Solid tumor
More
Phase 2 Clinical
Bafisontamab
 ( EGFR x c-Met )		Gastrointestinal Neoplasms
More
Phase 2 Clinical
EMB-07
 ( CD3 x ROR1 )		Prostatic Cancer
More
Phase 1
EMB-09
 ( OX40 x PDL1 )		Neoplasms
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free